For biotech VC fundraising, start with the evidence your science has produced and the milestone your next round will fund. Submit your startup on Round Funded to get matched with investors and focus your pitch on investors whose interests fit your company.
What makes biotech VC different from other fundraising?
Biotech investing centers on scientific progress, development risk, and the potential value of a product or platform. Unlike a business that can point primarily to revenue or customer growth, a biotech company needs to explain what its research has established and what must happen next.
The kind of company you are building also affects your investor search. A platform company may appeal to investors looking for an engine capable of producing a pipeline. A company developing a single asset may be better suited to a narrower set of investors. Make that distinction clear before you begin outreach.
Some firms also build companies internally rather than relying only on pitches from external startups. Flagship Pioneering, Third Rock, and ARCH Venture Partners are associated with incubating platform-science companies. This means you should research how a firm invests and creates companies, rather than assuming every potential investor follows the same process.
What evidence do biotech VC investors want to see?
In biotech, traction can be demonstrated through scientific milestones. Examples include target validation, preclinical results, IND acceptance, and Phase 1 readouts. Your pitch should state what the evidence supports, what remains unproven, and how the proposed financing moves the company toward its next important result.
The modality and research approach matter, too. AI-driven discovery companies are expected to show wet-lab validation. A computational approach without that validation may face skepticism, while computation combined with data can make a stronger case. If your company is a platform, explain how the platform could generate a pipeline. If you are developing a single asset, make the investment case for that asset clear.
Team composition is another part of the scientific story. Techbio teams that combine software founders with scientific co-founders are drawing interest from generalist technology investors. Show how your team’s expertise relates to the work ahead, rather than treating the team slide as a substitute for evidence.
How large can a biotech VC round be?
Round sizes vary with the company’s approach and the milestones being financed. Seed rounds commonly run $5M to $20M. At the platform end, Series A rounds of $50M to $100M+ are normal and may be released against milestone gates. These are market patterns, not forecasts for an individual startup.
Some significant rounds have two or three firms co-leading, which can distribute risk across a clinical timeline. For your own raise, explain the amount in terms of the work it supports and the decision point investors will be able to assess.
A milestone-based ask is more concrete than a request described only as runway. For instance, an $8M request to reach IND ties the amount to a specific goal. Connect the financing to the activities, expected result, and milestone that will inform the next decision.
How do you choose biotech VC firms and partners?
Create a focused list of 30 to 50 firms with portfolios adjacent to your science. Adjacency can help you find relevant experience without prioritizing investors whose existing work directly overlaps with your company.
Then go beyond the firm name. Identify partners who led investments closest to your modality or indication, and assess whether their interests fit your company. Firms can differ in how they build companies and where they invest: ARCH is comfortable with decade-long deep science, Flagship focuses on platform science and internal company creation, and Third Rock builds around unmet-need theses with substantial operational involvement.
Other firms have distinct profiles as well. Atlas focuses on disciplined, seed-led biotech creation. RA Capital invests from early rounds through public markets, while OrbiMed has a dedicated healthcare focus and global reach. Use these descriptions as starting points for fit research, then evaluate the relevance of a specific partner to your company. Submit your startup on Round Funded to get matched with investors as you begin organizing your search.
Indication also helps frame your research. Obesity-adjacent areas, neuro, and oncology are deep indication pools, and GLP-1 spillover supports metabolic science broadly. These areas are context for your search, not a reason to pitch an investor without checking their interests.
What should a biotech investor pitch include?
Lead with the data package. Present the key experiment, its validation status, and the milestone your financing is meant to reach. Then explain the company’s scientific approach and how the evidence supports its potential.
Put the team slide second, and connect founders’ and advisors’ expertise to the science and execution. Investors will need to assess both the evidence and the people responsible for advancing it.
Keep the ask specific. State how much you are raising, what work it will finance, and what result the work is intended to produce. A clear milestone gives investors a basis for evaluating the plan, while a general runway description leaves the purpose of the financing less defined.
A referral network can complement direct investor outreach. LabCentral bench access and an Engine affiliation may provide ways to reach such networks. The outreach approach recommends contacting 40 precise targets, following up on day 4 and day 10, and tracking engagement before spending on travel.
Round Funded covers tools for investor discovery, outreach, and pipeline organization. Its database covers 60,000+ active VCs, angels, family offices, and accelerators, searchable by stage, industry, geography, and check size. Investors are filtered to recent activity, with a check in roughly the last 6 months, and emails are verified. The product helps founders find investors, send pitches, and track replies. Outreach goes from your own Gmail, and AI drafts personalized emails and follow-ups for each investor. The fundraising pipeline keeps investors, stages, and next steps in one place.
Submit your startup to get matched with investors as one way to start organizing your investor search. These tools support outreach and tracking; they do not replace scientific diligence or a financing plan grounded in evidence.
How Round Funded helps biotech founders
- Submit your startup to get matched with investors.
- Search investors by stage, industry, geography, and check size.
- Use the database of active VCs, angels, family offices, and accelerators to research potential investors.
- Use AI to draft personalized investor outreach and follow-up emails from your own Gmail.
- Track investor stages and next steps in the fundraising pipeline.
Frequently Asked Questions
What does biotech VC mean?
Biotech VC refers to venture capital investment in biotechnology companies. The fundraising case often depends on scientific evidence, development milestones, and the potential of a product or platform.
What milestones can show biotech traction?
Examples include target validation, preclinical results, IND acceptance, and Phase 1 readouts. Explain what each result establishes and what still needs to be demonstrated.
How should you present an AI-driven discovery company?
Include wet-lab validation alongside the computational work. The pitch should explain how the data supports the approach and what milestone the next financing will fund.
How many firms should you research for a biotech raise?
A focused shortlist can include 30 to 50 firms with portfolios adjacent to your science. Research the relevant partners as well as the firms, especially who led investments closest to your modality or indication.
What are common biotech round sizes?
Seed rounds commonly run $5M to $20M. At the platform end, Series A rounds of $50M to $100M+ are normal and may be released against milestones. These ranges do not guarantee what a specific company can raise.